Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

200,000 Orion Corporation A shares converted into B shares

XPRO

ORION CORPORATION      STOCK EXCHANGE RELEASE 13 AUGUST 2015 at 9.30 a.m. EEST              

200,000 Orion Corporation A shares converted into B shares


In accordance with Section 3 of the Articles of Association of Orion Corporation, 200,000 A shares have been converted into 200,000 B shares. The conversion has been entered into the Trade Register on 13 August 2015.


The total number of shares in Orion Corporation is 141,257,828 which, after the conversion, consists of 39,425,774 A shares and 101,832,054 B shares.
 
  
Orion Corporation

Olli Huotari
SVP, Corporate Functions
  Jari Karlson
CFO
 
                                                            

                                                                  

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi

Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs.
Orion's net sales in 2014 amounted to EUR 1,015 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki.




This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orion Oyj via Globenewswire

HUG#1945341


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today